Eric Palmer of FiercePharma.com reports that in just one week the European Committee for Medical Products for Human Use (CHMP) has recommended ten new drugs for approval. In the mix of the ten drugs included three medicines to treat cancer from Dendreon, Bayer, and GlaxoSmithKline, and two biosimilars. The biosimilars will have the task of competing against the powerhouse rheumatoid arthritis drug Remicade. All of these drugs will be under close watch in the European markets to help predict how they will do in the US when rules are set in the future. Read the full article here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.